Preclinical pharmacokinetic and toxicological evaluation of MIF-1 peptidomimetic, PAOPA: Examining the pharmacology of a selective dopamine D2 receptor allosteric modulator for the treatment of schizophrenia

Peptides

Volumn 42, Issue , 2013, Pages 89-96

  Tan, Mattea L ^a   Basu, Dipannita ^a   Kwiecien, Jacek M ^a   Johnson, Rodney L ^b   Mishra, Ram K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Allosteric; Antipsychotic; D2 receptor; Pharmacokinetics; Schizophrenia; Toxicology

Indexed keywords

3 [(2 PYRROLIDINYLCARBONYL)AMINO] 2 OXO 1 PYRROLIDINEACETAMIDE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROMODULATION; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MSH RELEASE-INHIBITING HORMONE; PEPTIDOMIMETICS; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TISSUE DISTRIBUTION;

EID: 84874602231     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2013.02.004     Document Type: Article

References (27)

1. N. Abramson, and B. Melton Am Fam Physician 62 2000 2053 2060
2. M.G. Beyaert, R.P. Daya, B.A. Dyck, R.L. Johnson, and R.K. Mishra Eur Neuropsychopharmacol 2012 [Epub ahead of print]
3. M.J. Burns J Toxicol Clin Toxicol 39 2001 1 14
4. G.W. Caldwell, J.A. Masucci, Z. Yan, and W. Hageman Eur J Drug Metab Pharmacokinet 29 2004 133 143
5. J.M. Castellano, J. Batrynchuk, K. Dolbeare, V. Verma, A. Mann, and K.J. Skoblenick Peptides 28 2007 2009 2015
6. D.S. Dwyer, and D. Donohoe Pharmacol Biochem Behav 75 2003 255 260
7. B. Dyck, K. Guest, C. Sookram, D. Basu, R. Johnson, and R.K. Mishra Schizophr Res 125 2011 88 92
8. B.A. Dyck, M.G. Beyaert, M.A. Ferro, and R.K. Mishra Schizophr Res 130 2011 250 259
9. O.D. Howes, and S. Kapur Schizophr Bull 35 2009 549 562
10. R.S. Khan, C. Yu, A.J. Kastin, Y. He, R.H. Ehrensing, and H. Hsuchou Int J Pept 2010 article ID 537639, pages 1-10
11. A. Mann, V. Verma, D. Basu, K.J. Skoblenick, M.G. Beyaert, and A. Fisher Eur J Pharmacol 641 2010 96 101
12. J.S. Markowitz, C.S. Brown, and T.R. Moore Ann Pharmacother 33 1999 73 85
13. M. Mathews, and D.J. Muzina Cleve Clin J Med 74 2007 597 606
14. R.K. Mishra, E.R. Marcotte, A. Chugh, C. Barlas, D. Whan, and R.L. Johnson Peptides 18 1997 1209 1215
15. R.K. Mishra, L.K. Srivastava, and R.L. Johnson Prog Neuropsychopharmacol Biol Psychiatry 14 1990 821 827
16. Y.J. Moon, K. Sagawa, K. Frederick, S. Zhang, and M.E. Morris AAPS J 8 2006 E433 E442
17. H. Nasrallah Psychoneuroendocrinology 28 SUPPL. 1 2003 83 96
18. R.S. Obach, J.G. Baxter, T.E. Liston, B.M. Silber, B.C. Jones, and F. MacIntyre J Pharmacol Exp Ther 283 1997 46 58
19. C. Opgen-Rhein, and M. Dettling Pharmacogenomics 9 2008 1101 1111
20. M.C. Ott, R.K. Mishra, and R.L. Johnson Brain Res 737 1996 287 291
21. M.N. Pangalos, L.E. Schechter, and O. Hurko Nat Rev Drug Discov 6 2007 521 532
22. C. Sookram, M. Tan, R. Daya, S. Heffernan, and R.K. Mishra Synapse 65 2011 788 794
23. L.K. Srivastava, S.B. Bajwa, R.L. Johnson, and R.K. Mishra J Neurochem 50 1988 960 968
24. D.M. Taylor, and R. McAskill Acta Psychiatr Scand 101 2000 416 432
25. V. Verma, A. Mann, W. Costain, G. Pontoriero, J.M. Castellano, and K. Skoblenick J Pharmacol Exp Ther 315 2005 1228 1236
26. A.P. Watt, D. Morrison, K.L. Locker, and D.C. Evans Anal Chem 72 2000 979 984
27. K.L. Yu, G. Rajakumar, L.K. Srivastava, R.K. Mishra, and R.L. Johnson J Med Chem 31 1988 1430 1436